A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma

Mirabello, 2009, Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program, Cancer, 115, 1531, 10.1002/cncr.24121 Tirtei, 2021, Precision Medicine in Osteosarcoma: MATCH Trial and Beyond, Cells, 10, 10.3390/cells10020281 Chen, 2021, Advances in targeted therapy for osteosarcoma based on molecular classification, Pharmacol. Res., 169, 10.1016/j.phrs.2021.105684 Lu, 2022, Novel Immunotherapies for Osteosarcoma, Front. Oncol., 12 Marko, 2016, Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison, Pediatr. Blood Cancer, 63, 1006, 10.1002/pbc.25963 Zhang, 2022, Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future, Front. Pharmacol., 13 Paoloni, 2007, Comparative oncology today, Vet. Clin. North Am. Small Anim. Pract., 37, 1023, 10.1016/j.cvsm.2007.08.003 Tarone, 2022, Improving Osteosarcoma Treatment: Comparative Oncology in Action, Life (Basel), 12 Simpson, 2017, Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics, Acta Vet. Scand., 59, 71, 10.1186/s13028-017-0341-9 LeBlanc, 2020, Improving human cancer therapy through the evaluation of pet dogs, Nat. Rev. Cancer, 20, 727, 10.1038/s41568-020-0297-3 Tawa, 2021, Transcriptomic profiling in canines and humans reveals cancer specific gene modules and biological mechanisms common to both species, Plos Comput. Biol., 17, 10.1371/journal.pcbi.1009450 Rolih, 2017, CSPG4: a prototype oncoantigen for translational immunotherapy studies, J. Transl. Med., 15, 151, 10.1186/s12967-017-1250-4 Nicolosi, 2015, Theranostic impact of NG2/CSPG4 proteoglycan in cancer, Theranostics, 5, 530, 10.7150/thno.10824 Beard, 2014, Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells, J. Immunother. Cancer, 2, 25, 10.1186/2051-1426-2-25 Riccardo, 2019, Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma, Ther. Adv. Med. Oncol., 11, 10.1177/1758835919855491 Beard, 2013, Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy, Clin. Cancer Res., 19, 4941, 10.1158/1078-0432.CCR-13-1253 Ilieva, 2017, Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types, Front. Immunol., 8, 1911, 10.3389/fimmu.2017.01911 Tarone, 2021, Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation, 277 Riccardo, 2022, Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial, J. Immunother. Cancer, 10 Johansson, 2006, Responses of mice immunized with a DNA vaccine encoding carcinoembryonic antigen (CEA), Vaccine, 24, 4572, 10.1016/j.vaccine.2005.08.044 Riccardo, 2014, CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA, Clin. Cancer Res., 20, 3753, 10.1158/1078-0432.CCR-13-3042 Piras, 2017, Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination, Vet. Comp. Oncol., 15, 996, 10.1111/vco.12239 Zhao, 2021, Osteosarcoma: a review of current and future therapeutic approaches, Biomed. Eng. Online, 20, 24, 10.1186/s12938-021-00860-0 LeBlanc, 2021, Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats, Vet. Comp. Oncol., 19, 311, 10.1111/vco.12677 Marconato, 2022, A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy, Cancers (Basel), 14, 10.3390/cancers14051347 Mason, 2016, Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma, Clin. Cancer Res., 22, 4380, 10.1158/1078-0432.CCR-16-0088 Flickinger, 2018, Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress, Vaccines (Basel), 6 Oladejo, 2021, Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies, Front. Immunol., 12, 10.3389/fimmu.2021.642316 Musser, 2021, Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector, Vet. Comp. Oncol., 19, 92, 10.1111/vco.12642 Musser, 2019, Vaccine strain Listeria monocytogenes abscess in a dog: a case report, BMC Vet. Res., 15, 467, 10.1186/s12917-019-2216-y Hobernik, 2018, DNA Vaccines-How Far From Clinical Use?, Int. J. Mol. Sci., 19, 10.3390/ijms19113605 Riccardo, 2017, Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance, Curr. Top. Microbiol. Immunol., 405, 99 Mittelman, 1992, Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma, Proc. Natl. Acad. Sci. USA., 89, 466, 10.1073/pnas.89.2.466 Wang, 2005, Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2, Cancer Res., 65, 6976, 10.1158/0008-5472.CAN-04-2328 Price, 2011, CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma, Pigment Cell Melanoma Res., 24, 1148, 10.1111/j.1755-148X.2011.00929.x Yang, 2022, Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation, Transl. Oncol., 16, 10.1016/j.tranon.2021.101318 Menéndez, 2021, Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas, J. Clin. Med., 10 Lauvrak, 2013, Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes, Br. J. Cancer, 109, 2228, 10.1038/bjc.2013.549 Gvozdenovic, 2013, CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome, J. Bone Miner. Res., 28, 838, 10.1002/jbmr.1817 Cai, 2020, Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy, Cell. Mol. Immunol., 17, 227, 10.1038/s41423-019-0305-2 Liu, 2022, Current insight into the regulation of PD-L1 in cancer, Exp. Hematol. Oncol., 11, 44, 10.1186/s40164-022-00297-8 Koirala, 2016, Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma, Sci. Rep., 6, 10.1038/srep30093 Yoshida, 2019, Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers, Onco. Targets Ther., 12, 2513, 10.2147/OTT.S198421 Wang, 2013, B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS One, 8 Geoerger, 2017, A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab), J. Clin. Oncol., 35, 10524, 10.1200/JCO.2017.35.15_suppl.10524 de Jonge, 2021, Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues, Cancers (Basel), 13, 10.3390/cancers13040813 Boudin, 2022, CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response, J. Transl. Med., 20, 464, 10.1186/s12967-022-03679-y Zhu, 2022, Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications, Front. Immunol., 13 Goulart, 2012, Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer, PLoS One, 7, 10.1371/journal.pone.0033274 Matsuda, 2018, Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma, Clin. Exp. Metastasis, 35, 641, 10.1007/s10585-018-9928-4 Tada, 2022, Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab, Cancer Immunol. Immunother., 71, 851, 10.1007/s00262-021-03042-y Griffiths, 2020, Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy, Proc. Natl. Acad. Sci. USA., 117, 16072, 10.1073/pnas.1918937117 Wu, 2020, Immuno-genomic landscape of osteosarcoma, Nat. Commun., 11, 1008, 10.1038/s41467-020-14646-w Poon, 2020, Recent and current clinical trials in canine appendicular osteosarcoma, Can Vet. J., 61, 301 Grosenbaugh, 2011, Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor, Am. J. Vet. Res., 72, 1631, 10.2460/ajvr.72.12.1631 Bergman, 2006, Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center, Vaccine, 24, 4582, 10.1016/j.vaccine.2005.08.027 Manley, 2011, Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs, J. Vet. Intern. Med., 25, 94, 10.1111/j.1939-1676.2010.0627.x Eldridge, 2016, Defining Feasibility and Pilot Studies in Preparation for Randomised Controlled Trials: Development of a Conceptual Framework, PLoS One, 11, 10.1371/journal.pone.0150205 Oyama, 2017, Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges, J. Vet. Intern. Med., 31, 970, 10.1111/jvim.14744 Lancaster, 2019, Guidelines for reporting non-randomised pilot and feasibility studies, Pilot Feasibility Stud., 5, 114, 10.1186/s40814-019-0499-1 Maniscalco, 2013, PDGFs and PDGFRs in canine osteosarcoma: new targets for innovative therapeutic strategies in comparative oncology, Vet. J., 195, 41, 10.1016/j.tvjl.2012.05.003 Bookout, 2003, Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways, Nucl. Recept. Signal., 1, 10.1621/nrs.01012 Conti, 2013, The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells, FASEB J., 27, 4731, 10.1096/fj.13-230201 Riccardo, 2020, Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas, Vaccines (Basel), 8 Loukopoulos, 2007, Clinicopathological relevance of tumour grading in canine osteosarcoma, J Comp Pathol, 136, 65, 10.1016/j.jcpa.2006.11.005 Occhipinti, 2014, Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients, Clin. Cancer Res., 20, 2910, 10.1158/1078-0432.CCR-13-2663